Identifying risk factors of anti-TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease.

Journal: Journal of pediatric gastroenterology and nutrition
PMID: 38291690

Abstract

OBJECTIVES: While higher infliximab (IFX) trough concentrations (TCs) are associated with better outcomes in patients with inflammatory bowel disease (IBD), they could pose a risk for adverse events (AEs), including IFX-induced skin lesions. Therefore, we studied correlations between IFX TCs and occurrence of AEs in paediatric IBD patients.

Authors

  • Karen van Hoeve
    Department of Paediatric gastroenterology & Hepatology & Nutrition, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Debby Thomas
    Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Tom Hillary
    Department of Dermatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Ilse Hoffman
    Department of Paediatric gastroenterology & Hepatology & Nutrition, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Erwin Dreesen
    Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Keywords

External Resources

Popular Topics
Recent Journals